All News #Library
Rare Diseases
Zhimeng Biopharma`s KCNQ2/3 Opener Approved for ALS Phase 2/3
09 Jul 2025 //
PR NEWSWIRE
Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA
20 Oct 2023 //
PR NEWSWIRE

Market Place
Sourcing Support